Skip to content
Inciteful Med

Diagnosis & Understanding Your Lab Reports

Last updated:

Fabry disease is diagnosed using an alpha-Gal A enzyme assay for males and GLA gene sequencing for females. Key lab tests include Lyso-Gb3 to measure disease severity and track treatment progress, alongside baseline tests to monitor kidney, heart, and nerve function.

Key Takeaways

  • • Males are diagnosed using an alpha-Gal A enzyme assay, while females require GLA gene sequencing for an accurate diagnosis.
  • • Lyso-Gb3 is a crucial biomarker used to confirm the disease and monitor how well treatments are working.
  • • A complete diagnostic baseline must include kidney function tests, a cardiac MRI, and a neurological evaluation.
  • • Genetic testing will reveal if your specific mutation is amenable, meaning it might be treated with an oral medication.

A Fabry disease diagnosis is rarely a single event. It is a process that involves confirming the disease, understanding its specific subtype, and “staging” how much it has affected your body [1][2]. Understanding your lab reports is the best way to ensure you are receiving comprehensive care.

The Diagnostic Gold Standard

The way Fabry is diagnosed depends entirely on whether the patient is male or female.

  • For Males: An alpha-galactosidase A (α\alpha-Gal A) enzyme assay is the standard first step [3]. If enzyme activity is very low (usually less than 30% of normal), the diagnosis is confirmed [3][4].
  • For Females: Enzyme tests are highly unreliable [5]. Because of Lyonization (X-chromosome inactivation), a female’s blood may show “normal” enzyme levels even if she has severe disease in her organs [6][7]. Therefore, GLA gene sequencing is mandatory to confirm a diagnosis in women [1][5].

Key Biomarkers: Lyso-Gb3

You will likely see a test for Lyso-Gb3 on your lab reports. This is a soluble “waste product” that builds up in the blood when the α\alpha-Gal A enzyme isn’t working [8].

  • A Diagnostic Tool: It is highly sensitive and helps doctors confirm the diagnosis, especially in cases where genetic results are unclear [8][9].
  • A Progress Marker: Lyso-Gb3 levels correlate with disease severity—classic males typically have much higher levels than those with late-onset forms [10][11]. Doctors use this number as a “baseline” to see how well treatment is working over time [12][10].

The Completeness Checklist: Mandatory Baseline Tests

Once a diagnosis is confirmed, you need a “baseline” to understand your starting point. Use this checklist to audit your workup:

  • [ ] Genetic Testing: Identification of the specific GLA gene mutation [2][4].
  • [ ] Kidney Function (Renal):
    • eGFR: A blood test to see how well your kidneys filter waste [13].
    • Proteinuria (UPCR): A urine test to check for protein, which is an early sign of kidney stress [13][14].
  • [ ] Heart Assessment (Cardiac):
    • Cardiac MRI (CMR): This is superior to a standard ultrasound (echocardiogram) because it can detect early scarring (fibrosis) and lipid buildup using T1 mapping [15][16][17].
  • [ ] Neurological/Pain Exam: An evaluation of nerve pain (acroparesthesia) and sweating ability [2][4].

Understanding Your Mutation

Your lab report will list a specific mutation. Two terms are particularly important:

  1. Amenable Mutation: This means your specific genetic “misspelling” can be fixed by an oral medication called a pharmacological chaperone (migalastat) [18][19]. Not all mutations respond to this; some require intravenous (IV) enzyme replacement therapy [18].
  2. Variant of Unknown Significance (VUS): This means a mutation was found, but scientists aren’t yet sure if it causes Fabry disease or if it is a harmless variation [20][21]. If you have a VUS, your doctor will look closely at your Lyso-Gb3 levels and organ function to decide if treatment is necessary [20][22].

Frequently Asked Questions

Why do females need genetic testing instead of an enzyme test for Fabry disease?
Females require GLA gene sequencing because a biological process called X-chromosome inactivation can cause their blood to show normal enzyme levels even if they have severe organ damage. Because of this, standard enzyme tests are highly unreliable for diagnosing women.
What is Lyso-Gb3 and why is it tested?
Lyso-Gb3 is a waste product that builds up in the blood when the alpha-Gal A enzyme is not working properly. Doctors test for this biomarker to help confirm a diagnosis, measure disease severity, and track how well your treatment is working over time.
What does it mean if my GLA gene mutation is amenable?
An amenable mutation means your specific genetic change can potentially be treated with an oral medication called a pharmacological chaperone. Not all mutations respond to this therapy, and some may require intravenous enzyme replacement instead.
What baseline tests do I need after a Fabry disease diagnosis?
A complete baseline evaluation should include kidney function blood and urine tests, a cardiac MRI to check for early heart scarring, and a neurological exam to assess nerve pain and sweating ability.
What does a VUS result mean on my genetic report?
VUS stands for Variant of Unknown Significance, meaning a genetic mutation was found but experts are not yet sure if it causes Fabry disease or is harmless. If you have a VUS, your doctor will closely monitor your Lyso-Gb3 levels and organ function to decide if treatment is needed.

Questions for Your Doctor

  • • What is the specific mutation (genotype) in my/my child's GLA gene, and has it been classified as pathogenic or a variant of unknown significance (VUS)?
  • • Is my mutation 'amenable' to chaperone therapy, and does that mean an oral medication is an option for me?
  • • Can you explain our Lyso-Gb3 level and how we will use it to monitor the effectiveness of treatment over time?
  • • Since I am female, we are doing GLA gene sequencing because enzyme tests can be unreliable, correct?
  • • Are we scheduling a Cardiac MRI with T1 mapping and late gadolinium enhancement to look for early signs of heart involvement?

Questions for You

  • • Have I received copies of all my lab reports, including my genetic testing and enzyme activity results?
  • • Do I have a baseline measurement for my kidney function (eGFR) and the amount of protein in my urine (UPCR)?
  • • Have I shared my genetic test results with a genetic counselor to discuss what this means for my children and other relatives?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    [Fabry disease: A review].

    Michaud M, Mauhin W, Belmatoug N, et al.

    La Revue de medecine interne 2021; (42(2)):110-119 doi:10.1016/j.revmed.2020.08.019.

    PMID: 33172708
  2. 2

    Treatment of Anderson-Fabry Disease.

    Simonetta I, Tuttolomondo A, Daidone M, et al.

    Current pharmaceutical design 2020; (26(40)):5089-5099 doi:10.2174/1381612826666200317142412.

    PMID: 32183665
  3. 3

    When and How to Diagnose Fabry Disease in Clinical Pratice.

    Michaud M, Mauhin W, Belmatoug N, et al.

    The American journal of the medical sciences 2020; (360(6)):641-649 doi:10.1016/j.amjms.2020.07.011.

    PMID: 32723516
  4. 4

    [The neurological manifestations of Fabry disease. A review].

    Firsov KV, Kotov AS

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2016; (116(9)):98-105 doi:10.17116/jnevro20161169198-105.

    PMID: 27735906
  5. 5

    Diagnosis of Fabry Disease Using Alpha-Galactosidase A Activity or LysoGb3 in Blood Fails to Identify Up to Two Thirds of Female Patients.

    Duro G, Anania M, Zizzo C, et al.

    International journal of molecular sciences 2024; (25(10)) doi:10.3390/ijms25105158.

    PMID: 38791200
  6. 6

    Early Renal Involvement in a Girl with Classic Fabry Disease.

    Perretta F, Antongiovanni N, Jaurretche S

    Case reports in nephrology 2017; (2017()):9543079 doi:10.1155/2017/9543079.

    PMID: 29098097
  7. 7

    Diverse phenotypic expression associated with the same genetic variant in female heterozygote patients of Anderson-Fabry disease: a case series.

    Tomioka D, Kato K, Ozawa T, et al.

    European heart journal. Case reports 2021; (5(2)):ytaa538 doi:10.1093/ehjcr/ytaa538.

    PMID: 33598617
  8. 8

    A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.

    Stiles AR, Zhang H, Dai J, et al.

    Molecular genetics and metabolism 2020; (130(3)):209-214 doi:10.1016/j.ymgme.2020.04.006.

    PMID: 32418857
  9. 9

    Incidental finding of cornea verticillata or lamellar inclusions in kidney biopsy: measurement of lyso-Gb3 in plasma defines between Fabry disease and drug-induced phospholipidosis.

    Politei J, Frabasil J, Durand C, et al.

    Biochimica et biophysica acta. Molecular basis of disease 2021; (1867(1)):165985 doi:10.1016/j.bbadis.2020.165985.

    PMID: 33022387
  10. 10

    Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.

    Sakuraba H, Togawa T, Tsukimura T, Kato H

    Clinical and experimental nephrology 2018; (22(4)):843-849 doi:10.1007/s10157-017-1525-3.

    PMID: 29288396
  11. 11

    A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.

    Talbot A, Nicholls K, Fletcher JM, Fuller M

    Molecular genetics and metabolism 2017; (122(1-2)):121-125 doi:10.1016/j.ymgme.2017.08.004.

    PMID: 28847675
  12. 12

    The use and performance of lyso-Gb3 for the diagnosis and monitoring of Fabry disease: A systematic literature review.

    Ramaswami U, West ML, Tylee K, et al.

    Molecular genetics and metabolism 2025; (145(2)):109110 doi:10.1016/j.ymgme.2025.109110.

    PMID: 40328031
  13. 13

    Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes.

    Hughes DA, Bichet DG, Giugliani R, et al.

    Journal of medical genetics 2023; (60(7)):722-731 doi:10.1136/jmg-2022-108669.

    PMID: 36543533
  14. 14

    Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.

    Warnock DG, Thomas CP, Vujkovac B, et al.

    Journal of medical genetics 2015; (52(12)):860-6 doi:10.1136/jmedgenet-2015-103471.

    PMID: 26490103
  15. 15

    Early diagnosis of cardiac involvement in Anderson-Fabry disease using cardiac MRI parameters.

    Solomon L, Dwivedi G, Boon E, et al.

    Future cardiology 2025; (21(12)):1107-1116 doi:10.1080/14796678.2025.2550107.

    PMID: 40844021
  16. 16

    CT and MR Imaging of Cardiomyopathies in Clinical Practice-An Approach After an Abnormal Echocardiogram or Electrocardiogram.

    Monteiro P, Peixoto T, Rodrigues P, Carvalho JG

    Echocardiography (Mount Kisco, N.Y.) 2025; (42(2)):e70104 doi:10.1111/echo.70104.

    PMID: 39963998
  17. 17

    Cardiac magnetic resonance in Fabry disease.

    Lanzillo C, Fedele E, Martino A, et al.

    European heart journal supplements : journal of the European Society of Cardiology 2023; (25(Suppl C)):C200-C204 doi:10.1093/eurheartjsupp/suad045.

    PMID: 37125302
  18. 18

    Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?

    Perretta F, Jaurretche S

    Healthcare (Basel, Switzerland) 2023; (11(4)) doi:10.3390/healthcare11040449.

    PMID: 36832983
  19. 19

    A Kidney Transplant Recipient Treated With Migalastat for Fabry Disease for 33 Months.

    Eleftheriadis T, Divani M, Poulianiti C, et al.

    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2025; (23(5)):383-387 doi:10.6002/ect.2025.0063.

    PMID: 40548538
  20. 20

    D313Y variant in two related end-stage renal disease patients - Pathogenic or not yet?

    Vicente R, Santos I, Coimbra M, et al.

    Nefrologia 2023; (43(5)):636-639 doi:10.1016/j.nefroe.2022.01.011.

    PMID: 36517364
  21. 21

    Gene variants of unknown significance in Fabry disease: Clinical characteristics of c.376A>G (p.Ser126Gly).

    Lau K, Üçeyler N, Cairns T, et al.

    Molecular genetics & genomic medicine 2022; (10(5)):e1912 doi:10.1002/mgg3.1912.

    PMID: 35212486
  22. 22

    Elevated Lyso-Gb3 Suggests the R118C GLA Mutation Is a Pathological Fabry Variant.

    Talbot A, Nicholls K

    JIMD reports 2019; (45()):95-98 doi:10.1007/8904_2018_146.

    PMID: 30569317

This page explains Fabry disease diagnostic tests and lab reports for educational purposes. Always consult your healthcare provider or genetic counselor to interpret your specific results.

Stay up to date

Get notified when new research about Fabry disease is published.

No spam. Unsubscribe anytime.